- Home
- CBT vs PTGX Comparison
CBT vs PTGX Comparison
Compare CBT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBT | PTGX |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 5.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | CBT | PTGX |
|---|---|---|
| Price | $65.18 | $89.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $63.67 | ★ $86.44 |
| AVG Volume (30 Days) | 468.3K | ★ 898.7K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.02 | 0.72 |
| Revenue | ★ $3,713,000,000.00 | $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.92 | $296.47 |
| P/E Ratio | ★ $10.85 | $124.48 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $58.33 | $33.70 |
| 52 Week High | $108.93 | $93.25 |
Technical Indicators
Market Signals| Indicator | CBT | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 64.67 |
| Support Level | $61.78 | $83.52 |
| Resistance Level | $65.62 | $90.85 |
| Average True Range (ATR) | 1.89 | 2.63 |
| MACD | 0.83 | -0.33 |
| Stochastic Oscillator | 96.02 | 83.62 |
Price Performance
Historical ComparisonAbout CBT Cabot Corporation
Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products. The company organizes itself into the following operating segments based on the product type; the Reinforcement Materials segment which generates maximum revenue provides reinforcing carbon products used in tires, and industrial products such as hoses, belts, extruded profiles, and molded goods; and the Performance Chemicals segment aggregates the specialty carbons, specialty compounds, fumed metal oxides, battery materials, inkjet colorants, and aerogel product lines. Geographically, the company derives maximum revenue from its customers in Europe, the Middle East, and Africa and the rest from the Americas and Asia Pacific region.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.